{"id":47677,"date":"2022-08-25T18:02:20","date_gmt":"2022-08-25T16:02:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/"},"modified":"2022-08-25T18:02:20","modified_gmt":"2022-08-25T16:02:20","slug":"invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/","title":{"rendered":"Invictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device"},"content":{"rendered":"
\n

\nFirst of its kind incubator-based device to be reviewed by FDA<\/i><\/b>\n<\/p>\n

SAN ANTONIO–(BUSINESS WIRE)–Invictus Medical has submitted a De Novo<\/i> application to the FDA for its Neoasis\u2122 incubator-based active noise control device. FDA clearance is an essential step in the commercialization process of all medical devices, and this type of application is used for first-of-kind medical devices. By defining a new class of active noise control devices, Invictus has now established the special requirements for this entire device class.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWith this submission, Invictus has made a huge step towards deploying the Neoasis\u2122 active noise control device in neonatal intensive care units. It is well documented that a quieter environment has a positive impact, including improved sleep hygiene and weight gain in infants where both are critical for development,\u201d said George Hutchinson, Invictus Medical\u2019s Chief Executive Officer. \u201cThe Invictus team and our regulatory partners at ProximaCRO have prepared a substantial submission with guidance from the FDA and we\u2019re optimistic about a smooth review process.\u201d\n<\/p>\n

\n\u201cExcessive environmental noise has long been a concern for NICU admitted preterm infants due to the duration of their hospital stay, the constant exposure to alarms, and the exposure from noise secondary to ventilators and other respiratory equipment,\u201d said Dr Kaashif Ahmad of Pediatrix Neonatology of Houston, co-author of a study on the Neoasis\u2122 performance. \u201cExisting mitigation measures for neonatal noise exposure are inadequate.\u201d\n<\/p>\n

\nAfter a series of pre-submission consultative meetings with the FDA, Invictus Medical amassed comprehensive performance and safety data covering a wide range of conditions for the application. Pre-submission meetings are conducted to expedite the review process by establishing the FDA\u2019s expectations prior to the submission.\n<\/p>\n

\nThe Neoasis\u2122 is in development and is not currently commercially available.\n<\/p>\n

\nAbout Invictus Medical<\/b>\n<\/p>\n

\nInvictus Medical is a San Antonio, Texas-based medical device company that aims to ensure that children are able to attain their developmental milestones. As evidenced by their record of National Science Foundation and National Institutes of Health grants, Invictus Medical has been at the forefront of pediatric care since its founding in 2012. Invictus Medical is a privately held company. For more information about Invictus Medical, please see www.invictusmed.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nghutchinson@invictusmed.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

First of its kind incubator-based device to be reviewed by FDA SAN ANTONIO–(BUSINESS WIRE)–Invictus Medical has submitted a De Novo application to the FDA for its Neoasis\u2122 incubator-based active noise control device. FDA clearance is an essential step in the commercialization process of all medical devices, and this type of application is used for first-of-kind … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47677","6":"format-standard","7":"category-industry"},"yoast_head":"\nInvictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"First of its kind incubator-based device to be reviewed by FDA SAN ANTONIO–(BUSINESS WIRE)–Invictus Medical has submitted a De Novo application to the FDA for its Neoasis\u2122 incubator-based active noise control device. FDA clearance is an essential step in the commercialization process of all medical devices, and this type of application is used for first-of-kind ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-25T16:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220825005533\/en\/1553722\/21\/download.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Invictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device\",\"datePublished\":\"2022-08-25T16:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/\"},\"wordCount\":380,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005533\\\/en\\\/1553722\\\/21\\\/download.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/\",\"name\":\"Invictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005533\\\/en\\\/1553722\\\/21\\\/download.jpg\",\"datePublished\":\"2022-08-25T16:02:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005533\\\/en\\\/1553722\\\/21\\\/download.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005533\\\/en\\\/1553722\\\/21\\\/download.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Invictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/","og_locale":"en_US","og_type":"article","og_title":"Invictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device - Pharma Trend","og_description":"First of its kind incubator-based device to be reviewed by FDA SAN ANTONIO–(BUSINESS WIRE)–Invictus Medical has submitted a De Novo application to the FDA for its Neoasis\u2122 incubator-based active noise control device. FDA clearance is an essential step in the commercialization process of all medical devices, and this type of application is used for first-of-kind ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-25T16:02:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220825005533\/en\/1553722\/21\/download.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Invictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device","datePublished":"2022-08-25T16:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/"},"wordCount":380,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220825005533\/en\/1553722\/21\/download.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/","url":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/","name":"Invictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220825005533\/en\/1553722\/21\/download.jpg","datePublished":"2022-08-25T16:02:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220825005533\/en\/1553722\/21\/download.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220825005533\/en\/1553722\/21\/download.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/invictus-completes-important-milestone-towards-commercialization-with-fda-submission-for-nicu-active-noise-control-device\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Invictus Completes Important Milestone Towards Commercialization With FDA Submission For NICU Active Noise Control Device"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47677"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47677\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}